Drug

Immune Checkpoint Inhibitor

CI-DRUG-00000298Explore in graph →NCIt C143250 CIViC

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Jurisdictions	First approval	First trial
All cancers	Phase4	Phase 4	14	12	2	20	—	—	Oct 26, 2017
Malignant Lung Neoplasm	Phase4	Phase 4	4	4	1	5	—	—	Oct 26, 2017
Malignant Liver Neoplasm	Phase4	Phase 4	2	1	0	2	—	—	Jul 30, 2025
Malignant Kidney Neoplasm	Phase4	Phase 4	1	1	0	1	—	—	Jun 8, 2026
Malignant Nasopharyngeal Neoplasm	Phase3	Phase 3	1	1	1	1	—

Curated evidence

Clinical evidence (18)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–18 of 18 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
CDKN2A Loss1
Immune Checkpoint Inhibitor

Clinical trials

Trials with this intervention (32)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–32 of 32 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07572864	Neoadjuvant ICI and Mitochondrial Vaccine for Resectable HNSCC	recruiting	Phase 2	9	West China HospitalOTHER	1	Sep 17, 2026	clinicaltrials
NCT07759856	NK Cells Plus ICI for SCLC Maintenance(NK-ICI-SCLC)	recruiting	Phase 2	42

KMT2D Loss-of-function1
Immune Checkpoint Inhibitor	Colorectal Adenocarcinoma	Predictive	B	Supports Sensitivity Response	3	submitted	EID12583 In a retrospective TCGA cohort of microsatellite-instable colorectal adenocarcinoma (n = 43; KMT2D LOF = 16, WT = 27), KMT2D loss of function was associated with higher TMB (p < 0.001), higher neoanti… (full text at CIViC) PMID 39578878 · Takemon et al., 2024 · Open in CIViC	civic

KMT2D Loss-of-function1

Immune Checkpoint Inhibitor

Colorectal Adenocarcinoma

Predictive

Supports Sensitivity Response

submitted

EID12583

In a retrospective TCGA cohort of microsatellite-instable colorectal adenocarcinoma (n = 43; KMT2D LOF = 16, WT = 27), KMT2D loss of function was associated with higher TMB (p < 0.001), higher neoanti… (full text at CIViC)

PMID 39578878 · Takemon et al., 2024 · Open in CIViC

LRP1B Loss-of-function2
Immune Checkpoint Inhibitor	Lung Adenocarcinoma	Predictive	B	Supports Sensitivity Response	3	accepted	EID12652 In a retrospective LUAD cohort treated with PD-1 plus CTLA-4 blockade (n = 59; LRP1B-MT n = 15, LRP1B-WT n = 44), LRP1B-mutated tumors showed significantly longer PFS (log-rank p = 0.0016), along with… (full text at CIViC) PMID 37057124 · He et al., 2023 · Open in CIViC	civic
〃	Solid NeoplasmCURATED_BROADER	Predictive	B	Supports Sensitivity Response	3	accepted	EID12252 In this trial, 101 patients with solid tumours, including lung, prostate, sarcoma, melanoma, and breast cancer, harbouring LRP1B alterations were treated with immune checkpoint inhibitors. Most patien… (full text at CIViC) PMID 33653800 · Brown et al., 2021 · Open in CIViC	civic

ERCC2 Mutation + ERCC3 Mutation + ERCC4 Mutation + ERCC5 MutationERCC2 ERCC3 ERCC4 ERCC52
Immune Checkpoint Inhibitor	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	3	submitted	EID12647 In a retrospective pan-cancer ICI-treated cohort from MSKCC (cohort 3, n = 1661), ERCC2/ERCC3/ERCC4/ERCC5-mutated tumors demonstrated improved OS vs ERCC-WT tumors (HR 0.54, 95% CI 0.42-0.70; p < 0.00… (full text at CIViC) PMID 37626083 · Chen et al., 2023 · Open in CIViC	civic
〃	Melanoma	Predictive	B	Supports Sensitivity Response	3	submitted	EID12646 In a retrospective pan-cancer ICI-treated cohort from MSKCC (cohort 3, n = 1661), ERCC2/ERCC3/ERCC4/ERCC5-mutated tumors demonstrated improved OS vs ERCC-WT tumors (HR 0.54, 95% CI 0.42-0.70; p < 0.00… (full text at CIViC) PMID 37626083 · Chen et al., 2023 · Open in CIViC	civic